Literature DB >> 32033783

Diagnostic delay in wild type transthyretin cardiac amyloidosis - A clinical challenge.

Bertil Ladefoged1, Anne Dybro1, Jonas Agerlund Povlsen1, Henrik Vase1, Tor Skibsted Clemmensen1, Steen Hvitfeldt Poulsen2.   

Abstract

AIM: To determine the diagnostic delay in patients with wild-type transthyretin cardiac amyloiodosis (ATTRwt). To determine the clinical and echocardiogtraphic characteristics of patients with an early and a late diagnosis and to study the suspected diagnoses and identification of diagnostic "red flags" before the ATTRwt diagnosis was established.
METHODS: In 50 consecutive patients with ATTRwt diagnosed from 2017 to 2019, clinical and echocardiographic patient characteristics were investigated based on electronic patient charts and echocardiographic database review at Aarhus University Hospital, Denmark.
RESULTS: The median diagnostic delay was 13 months (2-47 months) and a diagnostic delay above 3 months was associated with more advanced symptoms and left ventricular (LV) diastolic dysfunction at the time of the diagnosis. Thirty patients (60%) were investigated for at least two non-ATTRwt diagnoses during the time period from the first cardiac examination to the time of the confirmed diagnosis. ATTR red flags were significantly less used in patients with the longest diagnostic delay (p < 0.001). Abormal LV global longitudinal strain (LV-GLS < 18%) and apical sparring ratio (APSR ≥ 1.5) were present in 96% and 94% of the ATTRwt patients, respectively.
CONCLUSION: The diagnostic delay in ATTRwt was substantial and a prolonged diagnostic delay was associated with more advanced symptoms and LV diastolic dysfunction at the time of the diagnosis. Established ATTR red flags are poorly utilized in the diagnostic process. Echocardiographic analysis of LV-GLS and APSR contributes significantly to the evaluation of LV myocardial performance and helps raise the suspicion of ATTRwt.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Delay; Diagnosis; Transthyretin; Wild type

Mesh:

Substances:

Year:  2020        PMID: 32033783     DOI: 10.1016/j.ijcard.2019.12.063

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

Review 1.  Echocardiographic assessment of cardiac amyloidosis.

Authors:  Tanushree Agrawal; Sherif F Nagueh
Journal:  Heart Fail Rev       Date:  2021-08-30       Impact factor: 4.654

Review 2.  Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Florint Kroi; Nils Fischer; Ana Gezin; Mahmoud Hashim; Mark Hermannes Rozenbaum
Journal:  Cardiol Ther       Date:  2020-12-14

3.  Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mark H Rozenbaum; Diana Tran; Rahul Bhambri; Jose Nativi-Nicolau
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-30       Impact factor: 3.283

4.  History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.

Authors:  Mounira Kharoubi; Mélanie Bézard; Arnault Galat; Fabien Le Bras; Elsa Poullot; Valérie Molinier-Frenkel; Pascale Fanen; Benoit Funalot; Anissa Moktefi; Jean-Pascal Lefaucheur; Mukedaisi Abulizi; Jean-François Deux; François Lemonnier; Soulef Guendouz; Coraline Chalard; Amira Zaroui; Vincent Audard; Emilie Bequignon; Diane Bodez; Emmanuel Itti; Luc Hittinger; Etienne Audureau; Emmanuel Teiger; Silvia Oghina; Thibaud Damy
Journal:  ESC Heart Fail       Date:  2021-10-29

5.  Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study.

Authors:  Oscar Westin; Jawad H Butt; Finn Gustafsson; Morten Schou; Morten Salomo; Lars Køber; Mathew Maurer; Emil L Fosbøl
Journal:  JACC CardioOncol       Date:  2021-08-17

6.  Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.

Authors:  Maaike Brons; Steven A Muller; Frans H Rutten; Manon G van der Meer; Alexander F J E Vrancken; Monique C Minnema; Annette F Baas; Folkert W Asselbergs; Marish I F J Oerlemans
Journal:  Eur Heart J Open       Date:  2022-02-24

7.  Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Authors:  Courtney M Campbell; Samantha LoRusso; Angela Dispenzieri; Arnt V Kristen; Mathew S Maurer; Claudio Rapezzi; Olivier Lairez; Brian Drachman; Pablo Garcia-Pavia; Martha Grogan; Doug Chapman; Leslie Amass
Journal:  Cardiol Ther       Date:  2022-05-18

8.  Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.

Authors:  Mark H Rozenbaum; Andrea Garcia; Daniel Grima; Diana Tran; Rahul Bhambri; Michelle Stewart; Benjamin Li; Bart Heeg; Maarten Postma; Ahmad Masri
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-08-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.